A carregar...
Publicação
Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 58.1 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Hidradenitis suppurativa (HS) is a chronic, recurrent
and debilitating skin disease of the hair follicle that is
accompanied by systemic inflammation. Treating HS is challenging,
and therapeutic tools as diverse as topical and systemic
antibiotics, biologics, intralesional steroids, surgical
procedures or light and laser therapies are frequently needed.
The combination of oral clindamycin and rifampicin has been
suggested as a possible treatment regimen.
Five studies have evaluated the efficacy of this combination,
the majority of which reported the use of clindamycin
600 mg daily + rifampicin 600 mg daily with an average
length of 10 consecutive weeks.1–5 In three out of four studies,
10-week follow-up yielded complete remission in 32%
(32/116) of patients1–3; in another study, a 1-year follow-up
demonstrated sustained efficacy in only seven of 26 patients.5
Scheinfeld has discussed why rifampicin is a key drug in the
treatment of HS, pointing out its antibacterial and anti-inflammatory
effects, its activity on bacterial biofilms, its effect
against granulomas and its immunomodulatory properties on
neutrophils. (...)
Descrição
Research letter
Palavras-chave
Hidradenitis Suppurativa Tuberculosis Infecções Respiratórias
Contexto Educativo
Citação
Br J Dermatol. 2017 Oct;177(4):e150-e151. doi: 10.1111/bjd.15500. Epub 2017 Sep 27.
Editora
Wiley/British Association of Dermatologists